Wednesday, June 10, 2026
🇺🇸 FDA

Patent directory · USPTO A61K / A61P

Patents matching “modified”

433 pharma patents match "modified" in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 433
Index total 30,257
Page 8 / 19

Quick answer

This filtered view shows 433 pharmaceutical patents matching "modified" in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

433 results for “modified” · 30,257 patents in full index Clear search

  1. US 10344281

    Functionally-modified oligonucleotides and subunits thereof

    Sarepta Therapeutics, Inc. · Granted Jul 9, 2019 · Expires Jul 4, 2039

    granted

  2. US 10328130

    Modified hyaluronidases and uses in treating hyaluronan-associated diseases and conditions

    HALOZYME, INC. · Granted Jun 25, 2019 · Expires Jun 20, 2039

    granted

  3. US 10308927

    Processing of a modified foot-and-mouth disease virus P1 polypeptide by an alternative protease

    The United States of America, as represented by the Secretary of Homeland Security · Granted Jun 4, 2019 · Expires May 30, 2039

    granted

  4. US 10286079

    Modified cytotoxins and their therapeutic use

    The Regents of the University of California · Granted May 14, 2019 · Expires May 9, 2039

    granted

  5. US 10278374

    Genetically modified mice and engraftment

    REGENERON PHARMACEUTICALS, INC. · Granted May 7, 2019 · Expires May 2, 2039

    granted

  6. US 10278372

    Genetically modified cells, tissues, and organs for treating disease

    Regents of the University of Minnesota · Granted May 7, 2019 · Expires May 2, 2039

    granted

  7. US 10266825

    Compositions comprising alternating 2′-modified nucleosides for use in gene modulation

    Ionis Pharmaceuticals, Inc. · Granted Apr 23, 2019 · Expires Apr 18, 2039

    granted

  8. US 10238750

    Porphyrin modified telodendrimers

    The Regents of the University of California · Granted Mar 26, 2019 · Expires Mar 21, 2039

    granted

  9. US 10239911

    Beta-D-2′-deoxy-2′-alpha-fluoro-2′-beta-C-substituted-2-modified-N6-substituted purine nucleotides for HCV treatment

    Atea Pharmaceuticals, Inc. · Granted Mar 26, 2019 · Expires Mar 21, 2039

    granted

  10. US 10233448

    Modified double-stranded RNA agents

    Alnylam Pharmaceuticals, Inc. · Granted Mar 19, 2019 · Expires Mar 14, 2039

    granted

  11. US 10226521

    Genetically modified Yersinia as vaccines against Yersinia species

    ARIZONA BOARD OF REGENTS FOR AND ON BEHALF OF ARIZONA STATE UNIVERSITY · Granted Mar 12, 2019 · Expires Mar 7, 2039

    granted

  12. US 10220042

    Modified release preparations containing oxcarbazepine and derivatives thereof

    Supernus Pharmaceuticals, Inc. · Granted Mar 5, 2019 · Expires Feb 28, 2039

    granted

  13. US 10211414

    Phosphorescent tetradentate metal complexes having modified emission spectra

    ARIZONA BOARD OF REGENTS FOR AND ON BEHALF OF ARIZONA STATE UNIVERSITY · Granted Feb 19, 2019 · Expires Feb 14, 2039

    granted

  14. US 10202602

    Oligonucleotide analogues having modified intersubunit linkages and/or terminal groups

    Sarepta Therapeutics, Inc. · Granted Feb 12, 2019 · Expires Feb 7, 2039

    granted

  15. US 10174302

    Modified L-asparaginase

    Jazz Pharmaceuticals Ireland Limited · Granted Jan 8, 2019 · Expires Jan 3, 2039

    granted

  16. US 10160961

    Factor VII polypeptides that are modified and uses thereof

    Catalyst Biosciences, Inc. · Granted Dec 25, 2018 · Expires Dec 20, 2038

    granted

  17. US 10123518

    Genetically modified non-human animals and methods of use thereof

    REGENERON PHARMACEUTICALS, INC. · Granted Nov 13, 2018 · Expires Nov 8, 2038

    granted

  18. US 10118961

    Modified antibody containing the cleavable peptide with the amino acid sequence TGRGPSWV

    CytomX Therapeutics, Inc. · Granted Nov 6, 2018 · Expires Nov 1, 2038

    granted

  19. US 10112900

    Modified amino acids

    Sutro Biopharma, Inc. · Granted Oct 30, 2018 · Expires Oct 25, 2038

    granted

  20. US 10111950

    Modified glycolipids and methods of making and using the same

    VACCINEX, INC. · Granted Oct 30, 2018 · Expires Oct 25, 2038

    granted

  21. US 10093900

    Genetically-modified cells comprising a modified human T cell receptor alpha constant region gene

    Precision BioSciences, Inc. · Granted Oct 9, 2018 · Expires Oct 4, 2038

    granted

  22. US 10093899

    Genetically-modified cells comprising a modified human T cell receptor alpha constant region gene

    Precision BioSciences, Inc. · Granted Oct 9, 2018 · Expires Oct 4, 2038

    granted

  23. US 10087210

    Modified nucleosides, analogs thereof and oligomeric compounds prepared therefrom

    Ionis Pharmaceuticals, Inc. · Granted Oct 2, 2018 · Expires Sep 27, 2038

    granted

  24. US 10081668

    Modified pigment epithelium-derived factor (PEDF) peptides and uses thereof for treating neovascular diseases, inflammatory diseases, cancer, and for cytoprotection

    BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA · Granted Sep 25, 2018 · Expires Sep 20, 2038

    granted

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.